Advice for healthcare professionals:
- cases of acute pancreatitis have been reported very infrequently during treatment with carbimazole
- if acute pancreatitis occurs, stop carbimazole treatment immediately
- do not use carbimazole in patients with a history of acute pancreatitis in association with previous treatment
- re-exposure may result in life-threatening acute pancreatitis with a decreased time to onset
- report suspected adverse drug reactions to the Yellow Card Scheme immediately
Carbimazole is authorised for use in the management of hyperthyroidism, including preparation for thyroidectomy and treatment before and after radioiodine treatment. Around 45,000–50,000 prescriptions for carbimazole a month are dispensed across GP practices in NHS England (data from openprescribing.net).
Carbimazole is a prodrug that undergoes rapid metabolism to the active metabolite, thiamazole. Thiamazole (synonym methimazole) is an antithyroid agent that acts by blocking the production of thyroid hormones. Thiamazole is not authorised for use in the UK.
Risk of acute pancreatitis
An EU review has found post-marketing reports of acute pancreatitis associated with the use of products containing carbimazole and thiamazole. In the UK, no Yellow Card reports of acute pancreatitis associated with carbimazole treatment have been received over a period of 55 years; however, a small number of reports have been received in other countries. Although the mechanism for development of acute pancreatitis is poorly understood, the presence of cases reporting recurrent acute pancreatitis with a decreased time to onset after re-exposure to carbimazole suggests a possible immunological mechanism.
Carbimazole must be immediately discontinued in patients who develop acute pancreatitis during treatment. Patients should be switched to an alternative therapy on the basis of an assessment of the individual benefits and risks.
Re-exposure to carbimazole must be avoided in patients who have previously experienced acute pancreatitis with carbimazole or thiamazole as re-exposure may result in recurrence of potentially life-threatening acute pancreatitis, with a decreased time to onset. The product information for products containing carbimazole is being updated to include risk of acute pancreatitis.
Direct Healthcare Professional Communication.
PRAC signal report for 26-29 November 2018 meeting.
Article citation: Drug Safety Update volume 12, issue 7: February 2019: 2.
Published 18 February 2019